Key points are not available for this paper at this time.
Gains in BCVA in this real-life study were lower than those observed in randomized clinical trials with ranibizumab, mainly due to undertreatment. Safety analysis of ranibizumab did not yield any new safety concerns.
Massin et al. (Tue,) studied this question.